Drugs / Frankincense
Frankincense
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07823868 | Jan → Dec 2027 expected | acute apical periodontitis, dental pulp necrosis | Oman Dental College | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04705714 | Jan → Mar 2021 | chronic periodontitis | Tanta University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Frankincense | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07823868 ↗ |
| Known as | Boswellia sacra | “Investigational root canal irrigant consisting of a standardized Boswellia sacra (frankincense) extract formulation, adjusted to a fixed concentration and pH, with batch...” NCT07823868 ↗ |
| Known as | Frankincense Extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04705714 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Boswellia sacra Flueck. oleoresin extract (frankincense) was traditionally used” NCT04705714 ↗ |
| Route | Other | “Delivered at approximately 5 mL per canal” NCT07823868 ↗ |